ESR1 Y537S and D538G: the mutations that switch ER on

Most resistance mutations weaken a drug’s grip on its target. The ESR1 hotspots do something stranger: they make the estrogen receptor stop needing estrogen at all. Y537S and D538G lock the receptor in its “on” conformation, so a class of drugs that works by starving the receptor of its hormone simply has nothing left to starve. That single mechanistic fact explains a decade of clinical failures and the one approval that beat them.

Where the mutations sit and what they do

ESR1 encodes estrogen receptor alpha (ERα). The receptor’s ligand-binding domain ends in a short stretch called helix 12 (H12), which acts as a lid. When estradiol (E2) binds, H12 folds down into the agonist position and creates the activation function-2 (AF-2) surface that recruits coactivators and turns on transcription. No hormone, no folded lid, no signal. That is the whole logic of endocrine therapy.

Y537 and D538 sit in the loop that connects helix 11 to H12 and are by far the two most frequently mutated residues, together accounting for more than half of all ESR1 mutants found in the clinic. Fanning et al. (2016) showed structurally what they do: Y537S, and to a lesser degree D538G, stabilize H12 in the agonist conformation even when no ligand is present. The receptor adopts the active shape on its own. This is constitutive, ligand- independent activation.

• Y537S replaces a tyrosine with serine, removing a hydrogen-bond network and letting H12 settle into the active pose. It is the strongest and most resistant of the hotspots.
• D538G sits one residue over and produces a milder version of the same effect via altered backbone flexibility in the H11-H12 loop.

Why they show up only after treatment

ESR1 mutations are vanishingly rare in untreated primary tumors but appear in roughly 20-40% of ER-positive metastatic cancers that have progressed on endocrine therapy (Toy et al., 2013; Robinson et al., 2013). They are an acquired escape, selected for under the pressure of estrogen deprivation. The clinical consequence is direct:

• Aromatase inhibitors (letrozole, anastrozole, exemestane) work by lowering circulating estrogen. A receptor that no longer needs estrogen is unaffected. AIs lose the most.
• Tamoxifen competes for the ligand pocket but the mutant’s shifted conformational equilibrium blunts its antagonism.
• Selective estrogen receptor degraders (SERDs)do not rely on hormone deprivation. They bind the receptor and drive its degradation, so an estrogen-independent receptor is still a target. This is why SERDs keep working when AIs fail.

Elacestrant: the SERD that earned an ESR1 label

Elacestrant (Orserdu) is an oral SERD. The FDA approved it on January 27, 2023 specifically for ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation, after progression on at least one line of endocrine therapy. It is the first targeted therapy approved on the basis of an ESR1 mutation, paired with a companion liquid-biopsy assay.

The approval rests on the phase III EMERALD trial (Bidard et al., 2022). Among the 228 patients with detectable ESR1 mutations, median progression-free survival was 3.8 months on elacestrant versus 1.9 months on standard-of-care endocrine therapy (hazard ratio 0.55). The absolute numbers look modest because this is a heavily pretreated metastatic population, but the relative benefit was concentrated in exactly the mutant subgroup the drug was designed for. Later analyses showed the benefit was largest in patients who had a longer prior run on a CDK4/6 inhibitor, a proxy for endocrine-sensitive disease.

Elacestrant retains activity against models carrying Y537S and D538G, the two hotspots that defeat aromatase inhibitors. The broader field, including next-generation oral SERDs and ER PROTACs, is being built around the same premise: degrade the receptor rather than try to out-compete a hormone the mutant no longer needs.

Try the docking yourself

Open Studio and pick ESR1 from the target catalog with the Y537S mutation chip. Dock a ligand against both the wild-type and Y537S ligand-binding domain and compare the poses: the mutant’s H12 is biased toward the agonist conformation, which is the structural reason antagonists lose grip. The interesting readout here is not a single binding score but the ΔΔ between wild-type and mutant, because the resistance story is conformational, not a clean loss of contacts. Liganx renders both receptors side by side so you can see it.

Liganx is molecular docking online: free, browser-based, and set up for mutation questions like this one. Running molecular docking against ESR1 Y537S is a fast way to build intuition for why a SERD beats an aromatase inhibitor in this setting.

Primary sources

• Fanning SW, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife 5, e12792 (2016). doi:10.7554/eLife.12792
• Toy W, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45, 1439-1445 (2013). doi:10.1038/ng.2822
• Bidard FC, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40, 3246-3256 (2022). doi:10.1200/JCO.22.00338